Injury to the blood-brain barrier exposes endothelium rich in von Willebrand factor (vWF), which may play a role in altered platelet aggregation following traumatic brain injury (TBI). Ristocetin is an antimicrobial substance that induces vWF-mediated aggregation of platelets. We examined these mechanisms in injured patients by measuring the aggregation response of platelets to stimulating agonists (including ristocetin) via whole-blood multiple-electrode platelet aggregometry. We hypothesized that patients with TBI have an altered platelet aggregation response to ristocetin stimulation compared with patients without TBI.
T rauma is a leading killer worldwide with 5 million deaths a year. [1] [2] [3] Hemorrhage accounts for 60% of deaths in patients with potentially salvageable injuries. [3] [4] [5] One-third of these hemorrhaging patients suffer from trauma-induced coagulopathy, a multifactorial disorder of inflammation and coagulation characterized by impaired clot formation from a distinct response to tissue injury and shock. 6, 7 More recently, investigations have begun to uncover the importance of the role of both platelets and endothelium in hemorrhage, organ failure, and mortality after injury. [8] [9] [10] [11] [12] [13] [14] [15] Platelets have a pivotal role in hemostasis via two key pathways: facilitation of procoagulant events and regulation of endothelial integrity. 16 However, the role of platelets in traumainduced coagulopathy is not well understood. 13, [17] [18] [19] [20] [21] [22] This hinders our ability to understand and appropriately provide plateletspecific targeted treatments to hemorrhaging trauma patients. It is known that postinjury thrombocytopenia is related to bleeding, progression of brain injury, and mortality, 20, 23 but accumulating evidence suggests that impaired platelet aggregation (independent of platelet count) following injury is common and associated with worse outcomes. 13, [17] [18] [19] [20] [21] [22] In fact, nearly half of all injured patients demonstrate evidence of impaired platelet aggregation despite having normal platelet counts. 13 Identifying the biology of this impaired platelet aggregation is critical, given the association with worse outcomes and higher mortality in these patients. 13, 14, [24] [25] [26] Postinjury platelet aggregation has been primarily quantified using multiple-electrode platelet aggregometry, which assays the aggregation response of platelets to various stimulating agonists via measurement of increasing electrical impedance in a sample of whole blood over a 6-minute time period.
Injuries characterized by significant tissue and endothelial damage have the strongest associations with impaired platelet aggregation. The most severely impaired platelet aggregation has been identified in patients with traumatic brain injury (TBI), high injury severity scores (ISS), or presence of shock and those who ultimately do not survive; these patients have increased platelet activation but impaired platelet aggregation. 13, 14, 27, 28 Together, these findings suggest that damage to endothelium, such as the blood-brain barrier, which is known to be rich in von Willebrand factor (vWF), 29 may lead to excessive platelet activation but impaired aggregation. 14, 27, 28, 30 Ristocetin is an antimicrobial substance that forms complexes with vWF causing conformational change in vWF and inducing the aggregation of platelets (Fig. 1B1 ). This relies on the binding of vWF to the platelet glycoprotein Ib (GPIb) receptor. Impaired platelet aggregation response to ristocetin stimulation is therefore consistent with either an absence of glycoprotein Ib (GPIb) receptors (Fig. 1B2 ) or a decrease in the amount or function of circulating vWF ( Fig. 1B3/B4 ). In addition, it has been demonstrated that a decrease in vWF, the carrier protein of factor VIII, results in a change in the circulating amount of factor VIII 31 ( Fig. 1B5) . Given these relationships, we examined these mechanisms as they relate to TBI by performing multiple-electrode platelet aggregometry, hypothesizing that patients with TBI have an altered platelet aggregation response to ristocetin stimulation compared with patients without TBI consistent with disruption of the vWF rich blood-brain barrier.
METHODS
Blood samples were collected, and multiple-electrode platelet aggregometry was performed on whole blood from 233 injured trauma patients on arrival to a Level I urban trauma emergency department as part of a longitudinal study examining perturbations in coagulation and inflammation after trauma (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Exclusions included patients who were pediatric, pregnant, or in custody; had burns greater than 20% body surface area; were transferred from another facility; did not require ICU-level care; or were atraumatic. Patients with thrombocytopenia (platelet count 150-400 Â 10 9 /L) or on antiplatelet or anticoagulant medications were excluded to control for This illustration represents a normal response to ristocetin stimulation. Ristocetin binds to vWF resulting in a conformational change to vWF. The ristocetin-vWF complex then binds to platelet GP1b receptors leading to ristocetin-induced aggregation. Impaired: (B2) Absence of GP1b receptors. This illustration represents an absence of GP1b receptors on platelets (Bernard-Soulier syndrome). Because of the absence of GP1b receptors, the ristocetin-vWF complex is unable to bind to platelets to induce aggregation. This disease state is rare and unlikely to be an explanation of the findings. (B3) Quantitative vWF dysfunction. This illustration represents a quantitative dysfunction of vWF as an explanation of impaired platelet aggregation response to ristocetin stimulation. It is plausible that injury causes the majority of the circulating vWF to be consumed in the process of binding to platelets to form clot. This may lead to a lack of circulating vWF left to complex with the ristocetin and therefore a downstream decrease in platelet aggregation via Gp1b receptors. (B4) Qualitative vWF dysfunction. This illustration represents a qualitative dysfunction of vWF as an explanation of impaired platelet aggregation response to ristocetin stimulation. It is plausible that a TBI-induced injurious effect on vWF function leads to an inability of ristocetin to bind and cause conformational change to vWF and therefore a downstream impairment in platelet aggregation via Gp1b receptors. (B5) Decreased factor VIII carrying capacity. This illustration represents an explanation of the downstream factor VIII effects of both quantitative (B3) and qualitative vWF dysfunction (B4). It is plausible that the elevated factor VIII activity in the patients with TBI may be explained by the decreased amount (B3) or function (B4) of circulating vWF due to impaired factor VIII carrying capacity. (C) Multiple-electrode platelet aggregometry. Platelet aggregation can be quantified using multiple-electrode platelet aggregometry, which assays the aggregation response of platelets to various stimulating agonists (ristocetin) via measurement of increasing electrical impedance in a sample of whole blood. Platelet aggregation responses to the various agonists are reported as AUC (U) over a 6-minute measurement period. Therefore, reduced platelet aggregation is measured as a lower AUC.
confounding effects on platelet aggregometry. Comprehensive injury, demographic, clinical, and outcome data were collected under a waiver of consent approved by the University of California Institutional Review Board. Traumatic brain injury was defined by clinical notes and chart review for imaging-identified intracranial injury and confirmed with Abbreviated Injury Score (AIS) head score of 3 or greater. Isolated TBI (iTBI) was defined as AIS head score of 3 or greater and AIS all other categories of less than 3. Traumatic brain injury + polytrauma (pTBI) was defined as AIS head score of 3 or greater and any other AIS categories of 3 or greater. Multiorgan failure was defined using the Denver Post-Injury Multiple Organ Failure Score. 32 Acute respiratory distress syndrome (ARDS) was defined by Berlin criteria, as described previously. 33 Coagulopathy was defined as international normalized ratio (INR) of 1.3 or higher. During the study period, there were no explicit changes to transfusion practices or protocols, and all blood product transfusions occurred following the blood draw.
Admission samples were collected via initial placement of a 16-gauge or larger peripheral intravenous line as described previously 13, 21, 34 in vacuum-sealed tubes containing 3.2% (0.109 M) sodium citrate. Platelet aggregation response to various stimulating agonists was assessed using multiple-electrode platelet aggregometry (Multiplate; Verum Diagnostica GmbH, Munich, Germany) immediately after sample collection. 13 Briefly, 0.3 mL of whole blood was diluted in warmed normal saline containing 3 mM CaCl 2 and incubated for 3 minutes at 37°C with continuous stirring in a Multiplate test cell. Each test cell contains two sets of 3-mm silver-coated copper wires, across which electrical resistance is measured at 0.57-second intervals. Platelet aggregation was stimulated by adenosine diphosphate (ADP, final concentration 6.5 μM; via P2 receptors), thrombin receptor-activating peptide 6 (TRAP, final concentration 32 μM; via PAR receptors), arachidonic acid (AA, final concentration 0.5 mM; via the cyclooxygenase pathway), collagen (final concentration 3.2 μg/mL; via GpIa/IIa and GpVI receptors), and ristocetin (final concentration 0.77 mg/mL; via vWF complex to Gp1b receptors). Platelet adhesion to the electrodes was detected as increasing electrical impedance, measured by duplicate sets of sensor wires in each test cell. Platelet aggregation responses to the various stimulating agonists are reported as area under the aggregation curve (AUC) in units over a 6-minute measurement period. Reference ranges for citrated whole blood were provided by the manufacturer. Samples were immediately centrifuged, and plasma extracted and stored at −80°C. Fibrinogen and factors II, V, VII, VIII, IX, and X were measured with a Stago Compact Coagulation Analyzer (Diagnostica Stago Inc., Parsippany, NJ) in accordance with manufacturer instructions.
Post hoc retrospective analysis of prospectively collected data was performed. The primary outcomes examined were platelet aggregation responses to stimulating agonists measured by multiple-electrode platelet aggregometry in TBI versus non-TBI cohorts. Data are presented as mean (±SD), median (interquartile range [IQR]), or percentage; univariate comparisons were made using Student t test for normally distributed data, Wilcoxon rank-sum or Kruskal-Wallis testing for nonparametric data, and Fisher exact test for proportions. Multivariate logistic regression was performed to examine the association of impaired platelet aggregation with TBI, controlling for confounding variables including extracranial injury severity (AIS in each category), gender, mechanism, and platelet count. An α < 0.05 was considered significant. Bonferroni corrections were used for multiple comparisons. All analysis was performed using Stata version 14 (StataCorp, College Station, TX).
RESULTS

Overall Cohort
The 233 patients were a relatively standard trauma population with respect to age (median, 34 years; IQR, 26-48 years) and gender (88% male). They were moderately injured with a median ISS of 9 (IQR, 12-15), and a mean base deficit of 2.2 ± 5.5. Five percent of the cohort was coagulopathic on presentation (INR ≥1.3), 25% required transfusion of products in the first 24 hours, and there was a 7% mortality at discharge ( Table 1 ). The overall cohort had a normal median platelet count of 263 Â 10 9 /L (IQR, 22-308 Â 10 9 /L; Table 1 ). The percent of patients with impaired platelet aggregation response to any stimulating agonist stimulation was 36% (10% ADP, 4% collagen, 17% TRAP, 18% AA, and 13% ristocetin; Table 2 ). Despite this, the median AUCs (and IQRs) for each agonist were within the normal manufacturer ranges ( Table 2) . 
Isolated TBI Versus pTBI Versus Non-TBI Cohorts
Twenty-three percent (54 patients) of the overall cohort had TBI (Table 1 ). The majority of those had iTBI (n = 36), and the remainder had pTBI (n = 18, Table 3A ). The TBI groups (iTBI and pTBI) were older, had higher rates of blunt trauma, and were overall more injured with worse outcomes (higher ISS, transfusion rates, ARDS rates, and mortality rates; all p < 0.0167 for multiple comparisons; Table 3A ). The TBI groups had significantly higher rates of transfusion of all products. Eleven percent of the iTBI and 33% of the pTBI patients were transfused platelets in the first 24 hours (compared with 4% in the non-TBI group, p < 0.0167 for multiple comparisons; Table 3A ). Despite this, there were no significant differences in the platelet aggregation response to ADP, collagen, TRAP, AA, or ristocetin stimulation between iTBI, pTBI, and non-TBI groups (Table 3B ). The highest rate of coagulopathy (INR ≥1.3) was in patients with pTBI (24% vs. 3%, p < 0.05; Table 3B ).
Any TBI (iTBI + pTBI) Versus No TBI
Although there were no differences in the platelet aggregation responses to various stimulating agonists in iTBI versus pTBI patients, the 54 patients with any TBI (iTBI + pTBI) had significantly impaired platelet aggregation response to ristocetin compared with those without TBI (median AUC 57 vs. 69, p = 0.03; Table 3C ). In multivariate analysis (controlling for extracranial injury severity [AIS in each category], gender, mechanism, and platelet count), there was a significant independent association of impaired platelet aggregation response to ristocetin stimulation with TBI. Patients with impaired platelet aggregation response to ristocetin stimulation were three times more likely to have TBI (odds ratio, 3.05; confidence interval, 1.01-9.15; p = 0.04).
The patients with TBI also had higher INR compared with those without TBI (Table 3C) . Corresponding with this, the TBI patients trended toward lower procoagulant factor activity for all factors except factor VIII. Interestingly, TBI patients had significantly higher activity of factor VIII (215% vs. 156%, p = 0.01; Table 3C ).
DISCUSSION
This study examined platelet aggregation responses to various stimulating agonists measured by multiple-electrode platelet aggregometry in injured patients and found that patients with TBI (both isolated and polytrauma) have impaired platelet aggregation response to ristocetin stimulation compared with patients without TBI (even when controlling for extracranial injury severity, gender, mechanism, and platelet count). This finding is consistent with the overall hypothesis that disruption of the vWF rich blood-brain barrier may drive downstream alterations of the vWF-platelet axis. Von Willebrand factor is stored in secretory Weibel-Palade bodies of endothelial cells and is released upon injury into both plasma and basement membrane spaces. Because ristocetin is an antimicrobial substance that forms complexes with vWF causing a conformational change in vWF that induces binding to glycoprotein Ib (GPIb) platelet receptors, the formation of ristocetin-vWF complexes leads to the aggregation of platelets (Fig. 1B1) . Thus, it is known that a lack of platelet aggregation response to ristocetin stimulation can be caused by an absence of glycoprotein Ib (GPIb) receptors on the platelet surface or by a decrease in the amount or function of vWF (Fig. 1B2-B4) .
Prior research suggests that certain injury patterns that are associated with significant endothelial damage may have a greater association with impaired platelet aggregation response to stimulating agonists in aggregometry assays. For example, Jacoby et al.
14 identified specific associations of impaired platelet aggregation response to aggregometry in TBI patients. Furthermore, they identified that platelets were activated but had impaired aggregation, which progressed at 24 hours after injury. Taken together, these results suggested that in TBI there is profound platelet activation leading to faster rates of adhesion and aggregation and a resultant prolonged period of impaired platelet responsiveness. This proposed mechanism may be induced by injury to the blood-brain barrier causing a robust endothelial mediated activation of platelets. Additional groups have identified similar associations in TBI patients and patients with other injury patterns consistent with endothelial damage (high ISS, shock states). 13, 27, 28, 30 Despite this, there have been no large prospective studies on the association of impaired postinjury platelet aggregation and biomarkers of endothelial injury (including vWF).
In this study, it is plausible that the impaired platelet aggregation response to ristocetin stimulation that we identified in TBI patients is due to a TBI-induced effect on vWF function (Fig. 1B4) or that the injury has caused the majority of the circulating vWF to be consumed in the process of binding to platelets in the clotting process (Fig. 1B3) . This latter mechanism could potentially lead to a lack of circulating vWF left to complex with the ristocetin and therefore a downstream impaired platelet aggregation response to ristocetin stimulation. Given the findings by de Oliveira et al. 35 that plasma vWF antigen levels increase in TBI patients compared with controls, the latter mechanism seems most likely. Levels of measurable vWF antigen may be increased in TBI, but the ability for ristocetin to stimulate circulating vWF to bind to platelets may be diminished because the vWF-platelet binding has already endogenously occurred from the injury itself.
Additionally, we identified that patients with TBI had a trend toward lower factor activity for all procoagulant factors except for factor VIII, which was significantly higher. It is biologically plausible that the elevated factor VIII activity in the patients with TBI may be explained by the decreased amount or function of circulating vWF that we identified (Fig. 1B5) . In studies of noninjured populations of patients, the ratio between circulating factor VIII and vWF antigen in several subtypes of von Willebrand Disease supports that the ratio of factor VIII:vWF is increased when vWF synthesis is reduced, thought to be secondary to decreased factor VIII carrying capacity. 31 This is an important finding, as studies have demonstrated that elevated factor VIII levels are a common risk factor for venous thromboembolism (prevalence of 25% among thrombosis patients and a 5Â increased risk), 36 which may partially contribute to the high rates of thromboembolic complications in TBI patients. 37 This study has multiple limitations. Because of the study design of a retrospective analysis of a prospectively followed cohort, we did not measure vWF antigen levels via enzyme-linked immunosorbent assays, which will be critical in the future to correlating vWF antigen levels to the mechanism of the impaired platelet aggregation response to ristocetin stimulation in this population. In addition, in order to control for the effects of thrombocytopenia on multiple-electrode platelet aggregometry, the patients included in this study were only moderately injured (due to the exclusion of all patients with a platelet count <150 Â 10 9 /L on presentation), and the results cannot be generalized to a severely injured population with thrombocytopenia. Lastly, given that it is known that impaired platelet aggregation response to ristocetin stimulation can be caused by an absence of glycoprotein Ib (GPIb) receptors on the platelet surface (consistent with Bernard-Soulier syndrome) or by an absence of vWF in circulation (von Willebrand disease type III), we recognize that there may be a small proportion of our patients who suffer from these diseases. However, these are rare conditions: Bernard-Soulier affects 1 in 1,000,000 patients, and type III von Willebrand disease affects 1 in 500,000 patients. 38 Because of the rarity of these disease states, it is unlikely that they had significant effects on this study.
A better understanding of how injury modulates interactions between platelets and endothelial cells will advance progress toward targeted therapies for postinjury hemorrhage and trauma-induced coagulopathy. Our findings demonstrate that platelet aggregation response to ristocetin stimulation differs between injured patients with and without TBI. We identified an impaired platelet aggregation response to ristocetin stimulation with a corresponding increase in factor VIII activity in TBI patients. It is plausible that the impaired platelet aggregation response to ristocetin stimulation can be explained by a TBIinduced effect on vWF function or that the majority of vWF has already bound to platelets following disruption of the blood-brain barrier with resultant exposure of vWF. Either way, it may be that cerebral endothelial injury increases the circulating factor VIII activity in the setting of impaired vWF factor VIII carrier function. Future studies of platelet aggregation after TBI that measure both quantity and function of vWF and corresponding factor activity will advance our understanding of platelet and endothelial biology after injury.
Finally, of particular importance is that although decades of retrospective and prospective evidence have identified that resuscitation with balanced ratios of blood products (red cells: plasma: platelets) improves outcomes after injury for the treatment of hemorrhaging trauma patients, 39 evidence suggests that the use of platelet transfusions following injury may not improve postinjury impairments in platelet aggregation. 40 Furthermore, the appropriate timing and dosage of platelet transfusions after injury remain unclear. Transfusion of platelets first (prior to other blood products) in massive transfusion decreases death from hemorrhage by improving hemostasis following injury. 33 However, early transfusion of platelets is strongly associated with the development of ARDS in patients with TBI. 41 Additionally, with increasing evidence highlighting the importance of the role of repair of the blood-brain barrier endothelium for neuroprotection and long-term outcomes, 15 improving resuscitation practices and targeting novel therapies for endothelial repair and maintenance of the platelet endothelial axis remain critical. Bambakidis and colleagues 42 recently identified that valproic acid, known to repair blood-brain barrier integrity in the setting of injury, may also have some effect on platelet aggregation.
Furthermore, there are multiple known therapies for vWF deficits outside the setting of injury including synthetic analogs of antidiuretic hormone such as desmopressin (ddAVP), vWF replacement therapy with purified and recombinant vWF, and estrogens. Desmopressin reversal of antiplatelet medicationinduced impaired platelet aggregation has been described, [43] [44] [45] [46] although large studies have not been performed. In addition, studies of the use of ddAVP for intracranial hemorrhage (traumatic and atraumatic) in the setting of impaired platelet aggregation due to antiplatelet medication demonstrate improved platelet aggregation, increased levels of measureable vWF, and decreased hematoma volume. [47] [48] [49] However, studies specific to the role of ddAVP in the reversal TBI-induced impaired platelet aggregation (and not antiplatelet-induced impaired platelet aggregation) following injury are needed. In addition, the effects of direct replacement of vWF in this setting are unknown. Specific to this, future investigations of the thrombotic effects of these therapies in the setting of injury will also be pivotal. These lines of investigation are particularly compelling for vWF-based therapeutic strategies in patients with TBI and hemorrhage. AUTHORSHIP A.J.R., L.Z.K., C.M.H., C.S.C., R.A.C., and M.J.C. contributed to study design, data collection, data analysis, data interpretation, writing, and clinical revision. A.S.C. contributed to study design, data collection, and clinical revision. A.T.F. contributed to data interpretation, writing, and clinical revision.
stronger". The authors studied the effects of known agonists of platelet aggregation in patients with and without traumatic brain injury (TBI), and found that of the multiple platelet aggregation agonists studied, only the von Willebrand Factor (vWF) dependent platelet aggregation agonist ristocetin (an antibiotic no longer used because it caused platelet aggregation in vivo) exhibited a difference in the degree of platelet aggregation based on the presence or absence of TBI. The authors showed that TBI patients also had higher Factor VIII activity, which is linked to qualitative or quantitative defects in von Willebrand factor (vWF). Although vWF was not measured in this study, the authors make the plausible connection to a defect in vWF, which is a clinically treatable condition. As the rest of the trauma community has plunged headlong into TEG, its variants, and the various phenotypes of hemostasis, we have discovered viscoelastic monitoring's various shortcomings in reproducibility and reliability in the presence of anticoagulant agents so common in our patients today. Basic mechanistic work is vitally important, if not as exciting to the clinical surgeon, to improve the outcomes of our future patients. The authors have provided a mechanistic basis for future research into vWF based treatment of TBI and hemorrhage, a leading cause of mortality in our patients.
